|
1
|
Duffy A, Capanu M, Abou-Alfa GK, Huitzil
D, Jarnagin W, Fong Y, D'Angelica M, Dematteo RP, Blumgart LH and
O'Reilly EM: Gallbladder cancer (GBC): 10-Year experience at
memorial sloan-kettering cancer centre (MSKCC). J Surg Oncol.
98:485–489. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jin LX, Pitt SC, Hall BL and Pitt HA:
Aggressive surgical management of gallbladder cancer: At what cost?
Surgery. 154:266–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Valle J, Kelley R, Nervi B, Oh D and Zhu
A: Biliary tract cancer. Lancet. 397:428–444. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lo JH, Agarwal R, Goff LW and Heumann TR:
Immunotherapy in biliary tract cancers: Current standard-of-care
and emerging strategies. Cancers (Basel). 15:33122023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oh DY, Lee KH, Lee DW, Kim TY and Bang YJ:
Durvalumab plus gemcitabine and cisplatin for advanced biliary
tract cancers: A phase III study (TOPAZ-1). Cancer Discov.
12:678–688. 2022.
|
|
6
|
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse
J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, et al: Pembrolizumab
in combination with gemcitabine and cisplatin compared with
gemcitabine and cisplatin alone for patients with advanced biliary
tract cancer (KEYNOTE-966): A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet. 401:1853–1865. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Z, Wang G, Du L, Zhao J, Pan L,
Zhang G, Wang F and Liu R: Case report: Persistent response to
combination therapy of pemigatinib, chemotherapy, and immune
checkpoint inhibitor in a patient with advanced intrahepatic
cholangiocarcinoma. Front Immunol. 14:11244822023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Zhang J, Ban X, Li Z and Fang Y: A
novel mixture of dose-fractioned radiation and PD-1 inhibitor
produces significant tumor control in a patient with advanced
intrahepatic cholangiocarcinoma: A case report. J Med Case Rep.
17:892023.
|
|
9
|
Liao W, Huang J, Liang Y, Zhou F and Pan
Z: PD-1 blockade and radiotherapy combination for advanced
Epstein-Barr virus-associated intrahepatic cholangiocarcinoma. J
Clin Oncol. 41:337–344. 2023.
|
|
10
|
He H, Zhao H, Chen L, Zhang Y and Yu H:
Long survival of immunotherapy plus paclitaxel in advanced
intrahepatic cholangiocarcinoma with high PD-L1 expression: A case
report. Cancer Biol Ther. 23:1–6. 2022.PubMed/NCBI
|
|
11
|
Balakrishnan A, Barmpounakis P, Demiris N,
Jah A, Spiers HVM, Talukder S, Martin JL, Gibbs P, Harper SJF,
Huguet EL, et al: Surgical outcomes of gallbladder cancer: The
OMEGA retrospective, multicentre, international cohort study.
EClinicalMedicine. 59:1019512023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
André T, Reyes-Vidal JM, Fartoux L, Ross
P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F
and Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary
tract carcinoma: A phase II study. Br J Cancer. 99:862–867. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hakeem AR, Papoulas M and Menon KV: The
role of neoadjuvant chemotherapy or chemoradiotherapy for advanced
gallbladder cancer-A systematic review. Eur J Surg Oncol. 45:83–91.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toyoda J, Sahara K, Takahashi T, Miyake K,
Yabushita Y, Sawada Y, Homma Y, Matsuyama R, Endo I and Pawlik TM:
Neoadjuvant therapy for extrahepatic biliary tract cancer: A
propensity score-matched survival analysis. J Clin Med.
12:26542023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miura Y, Ashida R, Sugiura T, Ohgi K,
Yamada M, Otsuka S, Todaka A and Uesaka K: Pathological complete
response achieved by gemcitabine plus cisplatin therapy for
initially unresectable advanced gallbladder cancer: A case report.
Surg Case Rep. 8:202022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Satyananda V, Chouliaras K, Cherkassky L
and Schwarz RE: A case from the future of HPB surgical oncology:
Resection of biliary tract cancer after immunotherapy. J Surg Case
Rep. 2021:rjab4142021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang S, Nie J, Tai S and Zheng T: PD-L1
inhibitor plus gemcitabine and cisplatin therapy followed by
conversion surgery for initially unresectable advanced gallbladder
cancer. BMJ Case Rep. 16:e2554032023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Q, Mu Y, Ji S, Liu Y, Lou Y, Wei S,
Dong X and Zhang B: Case report: Complete pathological remission of
human chorionic gonadotrophin-producing gallbladder carcinoma with
multiple liver metastases after treatment with chemotherapy plus an
immune checkpoint inhibitor. Front Immunol. 14:11735202023.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leong EKF, Tan NCH, Pang NQ and Kow AWC:
Case report: From palliative to potentially curative-the advent of
immunotherapy providing hope to advanced gallbladder
adenocarcinoma. Front Immunol. 15:13534302024. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Patel SP, Guadarrama E, Chae YK, Dennis
MJ, Powers BC, Liao CY, Ferri WA Jr, George TJ, Sharon E, Ryan CW,
et al: SWOG 1609 cohort 48: Anti-CTLA-4 and anti-PD-1 for advanced
gallbladder cancer. Cancer. Feb 15–2024.(Epub ahead of print).
|
|
22
|
Tan S, Yu J, Huang Q, Zhou N and Gou H:
PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for
advanced gallbladder cancer in a second-line setting: A
retrospective analysis of a case series. Front Oncol.
12:10060752022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rao J, Xia J, Yang W, Wu C, Sha B, Zheng
Q, Cheng F and Lu L: Complete response to immunotherapy combined
with an antiangiogenic agent in multiple hepatic metastases after
radical surgery for advanced gallbladder cancer: A case report. Ann
Transl Med. 8:16092020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Galdy S, Lamarca A, McNamara MG, Hubner
RA, Cella CA, Fazio N and Valle JW: HER2/HER3 pathway in biliary
tract malignancies; systematic review and meta-analysis: A
potential therapeutic target? Cancer Metastasis Rev. 36:141–157.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Koido S, Kan S, Yoshida K, Yoshizaki S,
Takakura K, Namiki Y, Tsukinaga S, Odahara S, Kajihara M, Okamoto
M, et al: Immunogenic modulation of cholangiocarcinoma cells by
chemoimmunotherapy. Anticancer Res. 34:6353–6361. 2014.PubMed/NCBI
|
|
26
|
Davis AA and Patel VG: The role of PD-L1
expression as a predictive biomarker: An analysis of all US food
and drug administration (FDA) approvals of immune checkpoint
inhibitors. J Immunother Cancer. 7:2782019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chmielecki J, Ross JS, Wang K, Frampton
GM, Palmer GA, Ali SM, Palma N, Morosini D, Miller VA, Yelensky R,
et al: Oncogenic alterations in ERBB2/HER2 represent potential
therapeutic targets across tumors from diverse anatomic sites of
origin. Oncologist. 20:7–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
